It is not uncommon for the child with a BT to
experience seizures. The goal of seizure management
at EOL is distinct from managing chronic
epilepsy, particularly in an unresponsive patient.
Midazolam is frequently used for its anticonvulsant
and sedative properties. It can be administered
subcutaneously/intravenously, via the
intranasal or buccal route, and as a rapid onset.
Seizures that are refractory to midazolam at EOL
can be often effectively manag